Swedish Orphan Biovitrum AB, or Sobi, and CTI BioPharma announced the completion of the acquisition of CTI by Sobi through its indirect wholly owned subsidiary Cleopatra Acquisition Corp. As a result of the transaction, CTI has become an indirect wholly owned subsidiary of Sobi, and the common stock of CTI will cease to be traded on the Nasdaq Stock Market.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CTIC:
- CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders
- CTI BioPharma Soars on $1.7B Acquisition by Orphan Biovitrum
- Sobi to Acquire CTI BioPharma
- CTI BioPharma Corp. (CTIC) Q1 Earnings Cheat Sheet
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue